Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Isis Fourth Quarter Strong, Antisense Rising

Mar 14 2008

• By Randall Osborne

Related Content

Bristol-Myers Squibb Licenses Cardiovascular Antisense Target From Isis

May 09 2007

Genta To File Complaint With FDA Over Statistical Analysis Of Genasense Data

Apr 30 2007

Genzyme, Isis Partner On Lipid Lowering Treatment Based On Antisense Technology

Jan 07 2008

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window